Investigating new ways to prevent aggressive tumors in patients with neurofibromatosis type 1.
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
This study is looking at people with neurofibromatosis type 1 (NF1) to find out what changes in their genes might cause certain tumors to become cancerous, and it’s exploring the idea of a vaccine that could help prevent these tumors from turning dangerous, which could really help improve health for NF1 patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10662510 on NIH RePORTER |
What this research studies
This research focuses on patients with neurofibromatosis type 1 (NF1), a genetic condition that increases the risk of developing certain tumors. The study aims to identify specific mutations that lead to the development of malignant peripheral nerve sheath tumors (MPNSTs) and explore the potential for a prophylactic vaccine to prevent these tumors from forming. By analyzing tumor-specific transcripts, the researchers hope to create a targeted immunoprevention strategy that could stop benign tumors from becoming malignant. This approach could significantly improve outcomes for NF1 patients at risk of developing aggressive tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 1 who are at risk of developing malignant peripheral nerve sheath tumors.
Not a fit: Patients without neurofibromatosis type 1 or those who do not have benign plexiform neurofibromas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that prevents the progression of benign tumors to malignant forms in NF1 patients.
How similar studies have performed: While the approach of using neoantigens for immunoprevention is innovative, similar strategies have shown promise in other cancer types, indicating potential for success.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Largaespada, David Andrew — University of Minnesota
- Study coordinator: Largaespada, David Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.